Barclays PLC Acquires 67,855 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Barclays PLC boosted its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 251.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,809 shares of the company’s stock after buying an additional 67,855 shares during the quarter. Barclays PLC owned approximately 0.08% of Organogenesis worth $271,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Organogenesis by 76.9% during the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after acquiring an additional 986,132 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares during the period. State Street Corp lifted its position in Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after purchasing an additional 9,090 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after purchasing an additional 23,675 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Organogenesis by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after purchasing an additional 24,878 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Stock Up 0.3 %

NASDAQ ORGO opened at $3.34 on Tuesday. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.57. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $419.94 million, a P/E ratio of -55.67 and a beta of 1.77. The stock’s 50-day moving average price is $3.50 and its 200-day moving average price is $3.10.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same period in the prior year, the firm posted $0.02 EPS. On average, equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Insider Activity

In other news, CEO Gary S. Gillheeney sold 18,416 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total value of $67,218.40. Following the completion of the transaction, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 278,116 shares of company stock worth $991,190 in the last three months. Company insiders own 36.90% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.